Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death.
Aged
Aged, 80 and over
Albuminuria
Biomarkers
/ blood
Creatinine
/ urine
Diabetes Mellitus, Type 2
/ blood
Disease Progression
Female
Humans
Ireland
Kidney
/ physiopathology
Longitudinal Studies
Male
Middle Aged
Prognosis
Receptors, Tumor Necrosis Factor, Type I
/ blood
Renal Insufficiency, Chronic
/ blood
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 09 2020
09 09 2020
Historique:
received:
24
03
2020
accepted:
05
08
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
16
3
2021
Statut:
epublish
Résumé
Identification of people with diabetes and chronic kidney disease at high-risk of early mortality is a priority to guide intensification of therapy. We aimed to investigate the complementary prognostic value of baseline urine albumin-to-creatinine ratio (uACR) and plasma soluble tumour necrosis factor receptor-1 (sTNFR1) with respect to early mortality and renal functional decline in a population with type 2 diabetes and advanced chronic kidney disease. We measured plasma sTNFR1 in people with type 2 diabetes (HbA
Identifiants
pubmed: 32908199
doi: 10.1038/s41598-020-71684-6
pii: 10.1038/s41598-020-71684-6
pmc: PMC7481247
doi:
Substances chimiques
Biomarkers
0
Receptors, Tumor Necrosis Factor, Type I
0
TNFRSF1A protein, human
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14852Subventions
Organisme : Wellcome Trust
ID : 203930/B/16/Z
Pays : United Kingdom
Références
Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24(2), 302–308 (2013).
doi: 10.1681/ASN.2012070718
Saran, R. et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 75(1), A6–A7 (2020).
doi: 10.1053/j.ajkd.2019.09.003
Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377(9), 839–848 (2017).
doi: 10.1056/NEJMoa1616011
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019).
doi: 10.1056/NEJMoa1811744
Martin, W. P. et al. Influence of referral to a combined diabetology and nephrology clinic on renal functional trends and metabolic parameters in adults with diabetic kidney disease. Mayo Clinic Proc. Innov. Quality Outcomes 1(2), 150–160 (2017).
doi: 10.1016/j.mayocpiqo.2017.07.003
Martin, W. P., Docherty, N. G. & Le Roux, C. W. Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. Expert Rev. Endocrinol. Metab. 2018, 1–12 (2018).
Holland, J. A., Martin, W. P., Docherty, N. G. & le Roux, C. W. Impact of intentional weight loss on diabetic kidney disease. Diabetes Obes. Metab. 21(10), 2338–2341 (2019).
doi: 10.1111/dom.13813
Martin, W. P., White, J., Lopez-Hernandez, F. J., Docherty, N. G. & le Roux, C. W. Metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and end-stage kidney disease; what are the unanswered questions? Front. Endocrinol. 11:289. https://doi.org/10.3389/fendo.2020.00289 (2020).
doi: 10.3389/fendo.2020.00289
Bullo, M., Garcia-Lorda, P., Megias, I. & Salas-Salvado, J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 11(4), 525–531 (2003).
doi: 10.1038/oby.2003.74
Hawari, F. I. et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc. Natl. Acad. Sci. USA 101(5), 1297–1302 (2004).
doi: 10.1073/pnas.0307981100
Van Zee, K. J. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89(11), 4845–4849 (1992).
doi: 10.1073/pnas.89.11.4845
Saulnier, P.-J. et al. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE cohort. Diabetes Care 37(5), 1425 (2014).
doi: 10.2337/dc13-2580
Saulnier, P.-J. et al. Association of circulating biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) with renal function decline in patients with type 2 diabetes: a french prospective cohort. Diabetes Care 40(3), 367 (2017).
doi: 10.2337/dc16-1571
Carlsson, A. C. et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. Cardiovasc Diabetol 15, 40–40 (2016).
doi: 10.1186/s12933-016-0359-8
Niewczas, M. A. et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23(3), 507 (2012).
doi: 10.1681/ASN.2011060627
Pavkov, M. E. et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 89(1), 226–234 (2016).
doi: 10.1038/ki.2015.278
Coca, S. G. et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J. Am. Soc. Nephrol. 28(9), 2786–2793 (2017).
doi: 10.1681/ASN.2016101101
Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25(5), 805–813 (2019).
doi: 10.1038/s41591-019-0415-5
Doody, A. et al. Validating the association between plasma tumour necrosis factor receptor 1 levels and the presence of renal injury and functional decline in patients with Type 2 diabetes. J. Diabetes Complicat. 32(1), 95–99 (2018).
doi: 10.1016/j.jdiacomp.2017.09.007
Levey, A. S. et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145(4), 247–254 (2006).
doi: 10.7326/0003-4819-145-4-200608150-00004
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).
doi: 10.7326/0003-4819-150-9-200905050-00006
Therneau TM: A Package for Survival Analysis in S. version 2.38. https://CRAN.R-project.org/package=survival . 2015.
Kassambara A, Kosinski M, Biecek P: survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.6. https://CRAN.R-project.org/package=survminer . 2019.
Gray B: cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2–9. https://CRAN.R-project.org/package=cmprsk . 2019.
Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82(13), 26 (2017).
doi: 10.18637/jss.v082.i13
Carrero, J. J. et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 91(1), 244–251 (2017).
doi: 10.1016/j.kint.2016.09.037
Tangri, N. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305(15), 1553–1559 (2011).
doi: 10.1001/jama.2011.451
Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. & Smith, D. H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 164(6), 659–663 (2004).
doi: 10.1001/archinte.164.6.659
Robles, N. R., Villa, J., Felix, F. J., Fernandez-Berges, D. & Lozano, L. Non-proteinuric diabetic nephropathy is the main cause of chronic kidney disease: results of a general population survey in Spain. Diabetes Metabolic Syndrome 11(Suppl 2), S777-s781 (2017).
doi: 10.1016/j.dsx.2017.05.016
Ferguson, T. W. & Tangri, N. Identifying potential biases in the nephrology literature. Adv. Chronic Kidney Disease 23(6), 373–376 (2016).
doi: 10.1053/j.ackd.2016.11.013
Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. CJASN 12(12), 2032–2045 (2017).
doi: 10.2215/CJN.11491116
Davidson, J. A. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad. Med. 131(4), 251–260 (2019).
doi: 10.1080/00325481.2019.1601404
Griffin, T. P., Martin, W. P., Islam, N., O’Brien, T. & Griffin, M. D. The promise of mesenchymal stem cell therapy for diabetic kidney disease. Curr. Diab. Rep. 16(5), 42 (2016).
doi: 10.1007/s11892-016-0734-6
Vos, F. E., Schollum, J. B. & Walker, R. J. Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. NDT Plus 4(6), 368–375 (2011).
pubmed: 25984197
pmcid: 4421676